meRfi®-GM
Multiple Myeloma (MM) / Plasmocytoma
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
Multiple myeloma (MM) is a B-cell malignancy for which new treatments are urgently needed
Multiple myeloma (MM) is a cancer of the plasma cells in the Bone marrow (BM) (BM) and is the second most common hematological malignancy worldwide.
Sun et al. 2022a Journal for ImmunoTherapy of Cancer 10: e003975
Multiple myeloma (MM) remains an incurable disease.
Multiple myeloma is predominantly a disease affecting elderly adults
Möller et …
References (Sources)
- A review discussing elotuzumab and its use in the second-line plus treatment of multiple myeloma
- Advances in immunotherapy in multiple myeloma
- Antigen-Mediated regulation in monoclonal gammopathies and myeloma
- Denosumab for myeloma bone disease: ready for prime time?
- Emerging immune targets for the treatment of multiple myeloma
- Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial
- When a Monoclonal Gammopathy Is Not Multiple Myeloma